1 completed, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow DisperSol Technologies, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PK and Dose Escalation and Expansion Study of DST-2970 Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone) - Prostate Cancer | Phase 1 | Terminated | DisperSol Technologies, LLC | 26 | 2020-01-31 | 2024-10-17 |
| Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation DST-0509, Jadenu, Exjade - Thalassemia Major | Phase 2 | Completed | DisperSol Technologies, LLC | 25 | 2019-08-20 | 2022-02-01 |
Prostatic Neoplasms (1) · Thalassemia (1) · beta-Thalassemia (1)
Abiraterone Acetate (1) · Deferasirox (1) · Prednisone (1) · abiraterone (1)
United States (2) · Thailand (1)